| Identification | More | [Name]
4'-Bromopropiophenone | [CAS]
10342-83-3 | [Synonyms]
1-(4-BROMOPHENYL)-1-PROPANONE
4-BROMOPHENYL ETHYL KETONE
4'-BROMOPROPIOPHENONE
4-BROMOPROPIOPHENONE
AURORA 22532
P-BROMOPROPIOPHENONE
Propiophenone, 4'-bromo-
4-Bromopropiophenone, 97+%
1-(4-bromophenyl)propan-1-one | [EINECS(EC#)]
233-745-7 | [Molecular Formula]
C9H9BrO | [MDL Number]
MFCD00000106 | [Molecular Weight]
213.07 | [MOL File]
10342-83-3.mol |
| Chemical Properties | Back Directory | [Appearance]
white to light yellow crystalline powder | [Melting point ]
45-47 °C(lit.)
| [Boiling point ]
138-140 °C14 mm Hg(lit.)
| [density ]
1.3841 (rough estimate) | [refractive index ]
1.5720 (estimate) | [Fp ]
>230 °F
| [storage temp. ]
Sealed in dry,Room Temperature | [solubility ]
Acetonitrile (Slightly), Chloroform (Slightly), Methanol | [form ]
powder to crystal | [color ]
White to Almost white | [BRN ]
1210311 | [InChI]
InChI=1S/C9H9BrO/c1-2-9(11)7-3-5-8(10)6-4-7/h3-6H,2H2,1H3 | [InChIKey]
UOMOSYFPKGQIKI-UHFFFAOYSA-N | [SMILES]
C(C1=CC=C(Br)C=C1)(=O)CC | [CAS DataBase Reference]
10342-83-3(CAS DataBase Reference) | [NIST Chemistry Reference]
1-Propanone, 1-(4-bromophenyl)-(10342-83-3) |
| Safety Data | Back Directory | [Hazard Codes ]
Xn,Xi | [Risk Statements ]
R22:Harmful if swallowed.
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S37/39:Wear suitable gloves and eye/face protection . | [WGK Germany ]
3
| [Hazard Note ]
Irritant | [HS Code ]
29147000 |
| Hazard Information | Back Directory | [Chemical Properties]
white to light yellow crystalline powder | [Uses]
4'-Bromopropiophenone is an electron-deficient aryl bromide that has the ability to self-polymerize using binary palladium catalyst. 4'-Bromopropiophenone is also used as a reagent in the synthesis of substituted 2-aminothiazoles (e.g. 2-Aminobenzothiazole [A593500]), compounds that are inhibitors of neuronal degeneration in patients with Alzheimer’s disease. |
|
|